European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

ZEUS study yields no survival benefits and positive results

Tue, 19 Mar 2013

The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress which ends today.

“There is no difference in the incidence of bone metastases and there is no difference in survival,” said Wirth in his brief presentation on whether Zometa can prevent bone metastases in high risk, metastatic prostate cancer patients. The ZEUS study, supported by the EAU Research Foundation, looked into the efficacy and safety results after a median follow-up of 50 months. Zoledronic acid (Zometa®) is a third-generation nitrogen-containing Bisphosphonate, approved in Europe and the US for the treatment of bone metastases in a broad range of tumours.

Zoledronic acid was expected to show its potential in preventing hormone therapy induced bone loss. Patients were randomised between standard treatment plus Zometa® 4 mg infusions every three months for a total of 48 months. “There were regional variations in the numbers of patients who developed bone metastases,” added Wirth as he noted that locally treated patients developed less bone metastases.

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer